Defective Hepatic Response to Interferon and Activation of Suppressor of Cytokine Signaling 3 in Chronic Hepatitis C

Gastroenterology

Volumn 132, Issue 2, 2007, Pages 733-744

  Huang, Ying ^a   Feld, Jordan J ^a   Sapp, Ronda K ^a   Nanda, Santosh ^a   Lin, Jiing Huey ^b   Blatt, Lawrence M ^b   Fried, Michael W ^c   Murthy, Krishna ^d   Liang, T Jake ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b InterMune Inc   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CONSENSUS INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 6; PEGINTERFERON ALPHA2A; SUPPRESSOR OF CYTOKINE SIGNALING 3; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIMPANZEE; CHRONIC HEPATITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER FUNCTION TEST; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA SEQUENCE; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS HEPATITIS; VIRUS LOAD; WESTERN BLOTTING;

EID: 33847016551     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.11.045     Document Type: Article

References (44)

1. Liang T.J., Rehermann B., Seeff L.B., and Hoofnagle J.H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132 (2000) 296-305
2. Feld J.J., and Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 (2005) 967-972
3. Tan S.L., He Y., Huang Y., and Gale Jr. M. Strategies for hepatitis C therapeutic intervention: now and next. Curr Opin Pharmacol 4 (2004) 465-470
4. Ank N., West H., and Paludan S.R. IFN-λ: novel antiviral cytokines. J Interferon Cytokine Res 26 (2006) 373-379
5. Blatt L.M., Davis J.M., Klein S.B., and Taylor M.W. The biologic activity and molecular characterization of a novel synthetic interferon-α species, consensus interferon. J Interferon Cytokine Res 16 (1996) 489-499
6. Barbaro G., and Barbarini G. Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon α-2b and ribavirin in combination: an Italian pilot study. Eur J Gastroenterol Hepatol 14 (2002) 477-483
7. Melian E.B., and Plosker G.L. Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 61 (2001) 1661-1691
8. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5 (2005) 375-386
9. Frese M., Schwarzle V., Barth K., Krieger N., Lohmann V., Mihm S., Haller O., and Bartenschlager R. Interferon-γ inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35 (2002) 694-703
10. Guo J.T., Bichko V.V., and Seeger C. Effect of α interferon on the hepatitis C virus replicon. J Virol 75 (2001) 8516-8523
11. Larkin J., Jin L., Farmen M., Venable D., Huang Y., Tan S.L., and Glass J.I. Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system. J Interferon Cytokine Res 23 (2003) 247-257
12. Tan H., Derrick J., Hong J., Sanda C., Grosse W.M., Edenberg H.J., Taylor M., Seiwert S., and Blatt L.M. Global transcriptional profiling demonstrates the combination of type I and type II interferon enhances antiviral and immune responses at clinically relevant doses. J Interferon Cytokine Res 25 (2005) 632-649
13. Soza A., Heller T., Ghany M., Lutchman G., Jake Liang T., Germain J., Hsu H.H., Park Y., and Hoofnagle J.H. Pilot study of interferon γ for chronic hepatitis C. J Hepatol 43 (2005) 67-71
14. Gale Jr. M., and Foy E.M. Evasion of intracellular host defence by hepatitis C virus. Nature 436 (2005) 939-945
15. Bode J.G., Ludwig S., Ehrhardt C., Albrecht U., Erhardt A., Schaper F., Heinrich P.C., and Haussinger D. IFN-α antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 17 (2003) 488-490
16. Duong F.H., Filipowicz M., Tripodi M., La Monica N., and Heim M.H. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 126 (2004) 263-277
17. Thomson M., Nascimbeni M., Gonzales S., Murthy K.K., Rehermann B., and Liang T.J. Emergence of a distinct pattern of viral mutations in chimpanzees infected with a homogeneous inoculum of hepatitis C virus. Gastroenterology 121 (2001) 1226-1233
18. Major M.E., Dahari H., Mihalik K., Puig M., Rice C.M., Neumann A.U., and Feinstone S.M. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology 39 (2004) 1709-1720
19. Logvinoff C., Major M.E., Oldach D., Heyward S., Talal A., Balfe P., Feinstone S.M., Alter H., Rice C.M., and McKeating J.A. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 101 (2004) 10149-10154
20. Feld J.J., Nanda S., Susan P., Schweigler L., Theodore D., Dougherty K., Zacks S., Shrestha R., Liang T.J., and Fried M.W. Hepatic gene expression profiles during treatment with peginterferon and ribavirin: identifying important molecular pathways for treatment response. Hepatology 44 (2006) 315A
21. Huang Y., Chen X.C., Konduri M., Fomina N., Lu J., Jin L., Kolykhalov A., and Tan S.L. Mechanistic link between the anti-HCV effect of interferon gamma and control of viral replication by a Ras-MAPK signaling cascade. Hepatology 43 (2006) 81-90
22. Der S.D., Zhou A., Williams B.R., and Silverman R.H. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc Natl Acad Sci U S A 95 (1998) 15623-15628
23. Radaeva S., Jaruga B., Hong F., Kim W.H., Fan S., Cai H., Strom S., Liu Y., El-Assal O., and Gao B. Interferon-α activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology 122 (2002) 1020-1034
24. Yasukawa H., Sasaki A., and Yoshimura A. Negative regulation of cytokine signaling pathways. Annu Rev Immunol 18 (2000) 143-164
25. Berg T., Sarrazin C., Herrmann E., Hinrichsen H., Gerlach T., Zachoval R., Wiedenmann B., Hopf U., and Zeuzem S. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37 (2003) 600-609
26. Su A.I., Pezacki J.P., Wodicka L., Brideau A.D., Supekova L., Thimme R., Wieland S., Bukh J., Purcell R.H., Schultz P.G., and Chisari F.V. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 99 (2002) 15669-15674
27. Bigger C.B., Guerra B., Brasky K.M., Hubbard G., Beard M.R., Luxon B.A., Lemon S.M., and Lanford R.E. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 78 (2004) 13779-13792
28. Klein S.B., Blatt L.M., and Taylor M.W. Cell surface binding characteristics correlate with consensus type I interferon enhanced activity. J Interferon Cytokine Res 16 (1996) 1-6
29. Lanford R.E., Guerra B., Lee H., Chavez D., Brasky K.M., and Bigger C.B. Genomic response to interferon-α in chimpanzees: implications of rapid down-regulation for hepatitis C kinetics. Hepatology 43 (2006) 961-972
30. Helbig K.J., Lau D.T., Semendric L., Harley H.A., and Beard M.R. Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. Hepatology 42 (2005) 702-710
31. He X.S., Ji X., Hale M.B., Cheung R., Ahmed A., Guo Y., Nolan G.P., Pfeffer L.M., Wright T.L., Risch N., Tibshirani R., and Greenberg H.B. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 44 (2006) 352-359
32. Zhu H., Nelson D.R., Crawford J.M., and Liu C. Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-α resistance. J Interferon Cytokine Res 25 (2005) 528-539
33. Vento S., Garofano T., Renzini C., Cainelli F., Casali F., Ghironzi G., Ferraro T., and Concia E. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 338 (1998) 286-290
34. Cacciola I., Pollicino T., Squadrito G., Cerenzia G., Orlando M.E., and Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 341 (1999) 22-26
35. Yoshimura A., Mori H., Ohishi M., Aki D., and Hanada T. Negative regulation of cytokine signaling influences inflammation. Curr Opin Immunol 15 (2003) 704-708
36. Blindenbacher A., Duong F.H., Hunziker L., Stutvoet S.T., Wang X., Terracciano L., Moradpour D., Blum H.E., Alonzi T., Tripodi M., La Monica N., and Heim M.H. Expression of hepatitis C virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology 124 (2003) 1465-1475
37. Kawaguchi T., Yoshida T., Harada M., Hisamoto T., Nagao Y., Ide T., Taniguchi E., Kumemura H., Hanada S., Maeyama M., Baba S., Koga H., Kumashiro R., Ueno T., Ogata H., Yoshimura A., and Sata M. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 165 (2004) 1499-1508
38. Yoshida T., Hanada T., Tokuhisa T., Kosai K., Sata M., Kohara M., and Yoshimura A. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med 196 (2002) 641-653
39. Koo B.C., McPoland P., Wagoner J.P., Kane O.J., Lohmann V., and Polyak S.J. Relationships between hepatitis C virus replication and CXCL-8 production in vitro. J Virol 80 (2006) 7885-7893
40. Polyak S.J., Khabar K.S., Rezeiq M., and Gretch D.R. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol 75 (2001) 6209-6211
41. Soo H.M., Garzino-Demo A., Hong W., Tan Y.H., Tan Y.J., Goh P.Y., Lim S.G., and Lim S.P. Expression of a full-length hepatitis C virus cDNA up-regulates the expression of CC chemokines MCP-1 and RANTES. Virology 303 (2002) 253-277
42. Radkowski M., Bednarska A., Horban A., Stanczak J., Wilkinson J., Adair D.M., Nowicki M., Rakela J., and Laskus T. Infection of primary human macrophages with hepatitis C virus in vitro: induction of tumour necrosis factor-α and interleukin 8. J Gen Virol 85 (2004) 47-59
43. Basu A., Meyer K., Lai K.K., Saito K., Di Bisceglie A.M., Grosso L.E., Ray R.B., and Ray R. Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. Virology 349 (2006) 347-358
44. Chen L., Borozan I., Feld J., Sun J., Tannis L.L., Coltescu C., Heathcote J., Edwards A.M., and McGilvray I.D. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128 (2005) 1437-1444